Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 tria -

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 tria
Information type: Randomised controlled trials
Source: The Lancet Oncology
Specialities: Cancers | Respiratory disorders
Summary
RCT (n=723) showed significantly improved median overall survival of 18.6 months in the atezolizumab plus chemotherapy group vs 13.9 months in chemotherapy group, p=0.033) and a significantly improved progression-free survival (7.0 months vs 5.5 months respectively, p<0.0001).
UKMi comment
A related editorial discusses the findings of the study in the context of the outcomes of the KEYNOTE-189 study which had evaluated pembrolizumab in combination with pemetrexed and showed an improved overall survival and progression-free survival regardless of PD-L1 status (but patients with high PD-L1 expression (>50%) seemed to benefit more in terms of overall survival from the combination than did patients with low or no PD-L1 expression).
Related links: Editorial